

## First Long-Term Clinical Study of Izokibep Published

**Solna, Sweden, September 12, 2023. The first publication outlining phase 2 efficacy and safety results from a long-term study of izokibep, a small biological IL-17A inhibitor, is now available online.**

The article, "Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II randomized placebo-controlled double-blind dose-finding multicentre study including long-term treatment", is published in the British Journal of Dermatology (BJD). The BJD is a top-ranked international journal in the field of dermatology.

*"Data from this phase 2 study indicate that the investigational agent izokibep is well tolerated and efficacious in the treatment of moderate-to-severe plaque psoriasis,"* said Nikolai Brun, Chief Medical Officer of Affibody. *"Encouragingly, the demonstration of long-term safety and efficacy over 3 years of treatment not only validates the Affibody® platform for long-term dosing but also places izokibep among the very frontrunners in the IL-17 space. This paves the way for higher doses or more frequent dosing to further enhance response rates, including in patients with hard-to-treat disease manifestations."*

### Citation and link to publication

Sascha Gerdes, Petra Staubach, Thomas Dirschka, Dieter Wetzel, Oliver Weirich, Johannes Niesmann, Rodrigo da Mota, Alex Rothhaar, Michael Ardabili, Gerda Vlasitz, Joachim Feldwisch, Lisa Osterling Koskinen, Sven Ohlman, Paul Peloso, Nikolai C. Brun, Fredrik Y. Frejd (2023): Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II randomized, placebo-controlled, double-blinded, dose-finding multicentre study including long-term treatment, BJD Published online September 12, 2023. DOI: 10.1093/bjd/ljad186.

Open-access link: <https://doi.org/10.1093/bjd/ljad186>.

### About BJD and Oxford University Press

The British Journal of Dermatology is a top-ranked international dermatology journal, publishing the highest-quality research to advance the understanding and management of skin disease to improve patient outcomes. The BJD is one of the journals of the British Association of Dermatologists (BAD), the professional membership body for dermatologists in the UK.

Oxford University Press (OUP) is BAD's publishing partner. OUP publishes over 500 academic and research journals covering a broad range of subject areas, two-thirds of which are published in collaboration with learned societies and other international organizations. OUP has been publishing journals for more than a century and, as the world's largest university press, has more than 500 years of publishing expertise. For more information, visit [academic.oup.com](http://academic.oup.com).

## About izokibep

---

Izokibep is small protein Affibody® therapeutic designed to inhibit IL-17A with high potency through tight binding affinity, the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody, and an albumin binding domain that results in improved pharmacokinetic (PK) properties. Clinical trial data support the hypothesis that these unique characteristics of izokibep may provide clinically meaningful and differentiated benefits for patients, including resolution of key manifestations of disease.

Izokibep is being evaluated in multiple late-stage trials in moderate-to-severe hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis, with plans to initiate an additional Phase 3 program in axial spondyloarthritis (AxSpA).

Affibody has licensed izokibep, to ACELYRIN, INC. and Inmagene Biopharmaceuticals Co. Ltd., while retaining an option to co-promote in the Nordic region.

## Attachments

---

[First Long-Term Clinical Study of Izokibep Published](#)